The Mission Report


26th Annual
ROTH Conference
March 9-12, 2014 - Ritz-Carlton, Dana Point

ROTH Capital Partners is a relationship-driven investment bank that primarily focuses on connecting small-cap publicly traded companies with institutional investors. This year's annual ROTH conference will take place at The Ritz Carlton located in Dana Point, CA, on March 17-12. Bringing together executives from more than 400 growth companies, the 26th Annual ROTH Conference is one of the largest of its kind in the U.S. For more information on ROTH Capital Partners, visit

Presenting Companies: A-E F-J K-O P-T U-Z


5Barz International, Inc. (BARZ)

5Barz International, Inc. (OTC: BARZ) business is focused on the global commercialization of a patented product technology branded under the name 5BARz™. 5BARz™ is a cellular network infrastructure device for use in the small office, home or for when users are mobile. 5BARz™ incorporates a patented technology to create a highly engineered, single-piece, plug 'n play unit that strengthens weak cellular signals to deliver high quality signals for voice, data and video reception on cell phones and other cellular equipped devices. For more information, visit the company’s website at

Abtech Holdings, Inc. (ABHD)

Abtech Holdings, Inc. (OTC: ABHD) is an environmental technology and engineering firm developing solutions for communities, industries, and governments that improve the quality of limited water resources and address issues of water pollution and contamination. AbTech's offerings include the ground-breaking, new antimicrobial technology known as Smart Sponge Plus, which is effective in reducing coliform bacteria found in storm water and industrial and municipal wastewater. For more information, visit the company’s website at

ACADIA Pharmaceuticals, Inc. (ACAD)

ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) is a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. The company’s pipeline of product includes pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis. ACADIA also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan Inc., and two preclinical programs directed at Parkinson’s disease and other neurological disorders. For more information visit the company’s Web site at

Acacia Research Corp. (ACTG)

Acacia Research Corp. (NASDAQ: ACTG) is a provider of patent licensing. By partnering with inventors and patent owners, the company combines legal and technology knowledge with robust patent assets to unlock financial value. An intermediary in the patent market, Acacia facilitates efficiency and delivers monetary rewards to the patent owner. Through Q3 2013, the company has generated gross licensing revenue of $987 million, and has returned more than $437 million to its patent partners. For more information, visit the company’s website at

AcelRx Pharmaceuticals, Inc. (ACRX)

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx has submitted an NDA to the FDA seeking approval for Zalviso™, the company’s lead product candidate, for the treatment of moderate-to-severe acute pain in adult patients in the hospital setting. The company has three additional pain treatment product candidates, ARX-02, ARX-03 and ARX-04. For more information, visit the company’s website at

Active Power, Inc. (ACPW)

Active Power, Inc. (NASDAQ: ACPW) designs and manufactures uninterruptible power supply (UPS) systems and modular infrastructure solutions that enable data centers and other mission critical operations. The company's products and solutions are built with pride in Austin, Texas, at a state-of-the-art, ISO 9001:2008 registered manufacturing and test facility. Global customers are served via Austin and three regional operations centers located in the United Kingdom, Germany and China, that support the deployment of systems in more than 50 countries. For more information, visit the company’s website at

Actuate Corp. (BIRT)

Actuate Corp. (NASDAQ: BIRT) provides software to more than 3 million BIRT developers and OEMs who build scalable, secure solutions designed to save time and improve brand experience by delivering personalized analytics and insights. Actuate founded and supports BIRT, the open source IDE; and develops BIRT iHub™, a deployment platform designed to improve productivity of developers working on customer facing applications. BIRT Analytics™ delivers self-service predictive analytics to enhance customer engagement using Big Data. BIRT Content Services™ enables organizations to transform, process, personalize, archive and deliver high-volume content. For more information, visit the company’s website at

Acura Pharmaceuticals, Inc. (ACUR)

Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) is a specialty pharmaceutical company utilizing its proprietary AVERSION® and IMPEDE® technologies to address medication abuse and misuse. The first two commercial products utilizing Acura’s tamper-resistant technologies are OXECTA® and NEXAFED®. In addition, the company has seven other abuse deterrent products in development: Hydrocodone bitartrate/acetaminophen tablets, oxycodone HCl/acetaminophen tablets, hydromorphone tablets, morphine tablets, oxymorphone tablets, tramadol tablets and methadone tablets. For more information, visit the company’s website at

Advanced Emissions Solutions, Inc. (ADES)

Advanced Emissions Solutions, Inc. (NASDAQ: ADES) is the holding entity for a family of companies that provide emissions solutions to customers in the power generation and other industries. ADA-ES, Inc. supplies activated carbon injection systems for mercury control, dry sorbent injection systems, technology services and other offerings. Clean Coal Solutions, LLC provides ADA's patented RC CyClean™ technology, patent pending M-45™ and M-45-PC™ technologies. BCSI, LLC manufactures engineered emissions control technologies, bulk material handling equipment, bulk storage systems, water/waste water treatment equipment, and custom components. For more information, visit the company’s website at

Adept Technology, Inc. (ADEP)

Adept Technology, Inc. (NASDAQ: ADEP) provides intelligent robots, autonomous mobile solutions and services designed to enable customers to achieve maximum productivity in their assembly, handling, packaging, testing, and logistical processes. Through a comprehensive portfolio of high-performance motion controllers, application development software, vision-guidance technology and high-reliability robot mechanisms with autonomous capabilities, Adept provides specialized robotics systems and services to high-growth markets including medical, electronics, food and semiconductor; as well as to traditional industrial markets. For more information, visit the company’s website at

Aerie Pharmaceuticals, Inc. (AERI)

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies. The company is preparing for two Phase III registration trials to demonstrate non-inferiority of IOP lowering for AR-13324 (dosed once daily) compared to timolol (dosed twice daily). Aerie has also started a phase IIb clinical trial of its fixed-dose combination product PG324, where the primary efficacy endpoint will be to demonstrate superiority of PG324 to each of its components. For more information, visit the company’s website at

AeroGrow International, Inc. (AERO)

Founded in 2002 in Boulder, Colorado, AeroGrow International, Inc. (OTC: AERO) is dedicated to the research, development and marketing of the AeroGarden line of dirt-free indoor gardens. AeroGardens allow anyone to grow farmer's market fresh herbs, salad greens, tomatoes, chili peppers, flowers and more, indoors, year-round, so simply and easily that no green thumb is required. For more information, visit the company’s website at

Alchemia Ltd. (AEMAF)

Alchemia Ltd. (OTC: AEMAF) is a drug discovery and development company marketing FDA approved fondaparinux, an injectible antithrombotic in the US, as well as other major markets via partner Dr. Reddy's Laboratories. The Company is also developing a late stage oncology product pipeline with multiple ongoing trials through its proprietary HyACT drug delivery platform, which targets anti-cancer drugs to solid tumours. Lead asset HA-Irinotecan is in a pivotal Phase III clinical trial for the treatment of metastatic colorectal cancer. For more information, visit the company’s website at

Alexza Pharmaceuticals, Inc. (ALXA)

Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. The company’s products are based on its Staccato system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner. FDA-approved ADASUVE (Staccato loxapine) is Alexza's first commercial product. For more information, visit the company’s website at

Align, Inc. (ALGN)

Align, Inc. (NASDAQ: ALGN) is a global medical device company and inventor of the Invisalign system. The company has also developed a suite of related products, such as the Invisalign system of clear aligner treatments, the iTero scanner, and OrthoCAD services to help dental professionals achieve clinical results and deliver effective, cutting-edge dental options for their patients. Founded in 1997, Align received FDA clearance in 1998 and began its first commercial sales of Invisalign to U.S. orthodontists in 1999. For more information, visit the company’s website at

Alliqua, Inc. (ALQA)

Alliqua, Inc. (NASDAQ: ALQA) provides advanced wound care solutions through its extensive sales and distribution network. Alliqua’s offers a suite of technological solutions to enhance the wound care practitioner's ability to deal with the challenges of healing both chronic and acute wounds. Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its proprietary hydrogel technology. Alliqua is also developing opportunities to use this same hydrogel technology as a transdermal drug delivery vehicle. For more information, visit the company’s website at

Alter NRG Corp. (ANRGF)

Alter NRG Corp. (OTC: ANRGF, TSX: NRG) provides alternative energy solutions to meet the growing demand for environmentally responsible and economically viable energy. The company works toward making landfills obsolete and to replace incineration with more efficient and environmentally sustainable plasma conversion technology. Alter NRG markets and sells the Westinghouse Plasma technology via subsidiary Westinghouse Plasma Corp., which has created plasma gasification technology converting a variety of waste into clean syngas that can be used for a variety of energy outputs. For more information, visit the company’s website at

American Apparel, Inc. (APP)

American Apparel, Inc. (NYSE: APP) is a Los Angeles-based vertically integrated manufacturer, distributor, and retailer of branded fashion basic apparel. As of February 1, 2014, American Apparel operated 247 retail stores in 20 countries, including the United States, Canada, Mexico, Brazil, United Kingdom, Ireland, Austria, Belgium, France, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, Australia, Japan, South Korea, and China. American Apparel also operates a global e-commerce site that serves more than 60 countries, and operates a wholesale business that supplies T-shirts and other casual wear to distributors and screen printers. For more information, visit the company’s website at

American Electric Technologies, Inc. (AETI)

American Electric Technologies, Inc. (NASDAQ: AETI) provides power delivery solutions to the global energy industry. South Coast Electric Systems L.L.C., a subsidiary, services Gulf Coast marine and vessel customers. Based in Houston, Texas, the company has global sales, support and manufacturing operations in Beaumont, Texas, Keystone Heights, Florida and Bay St. Louis, Mississippi. In addition, American Electric Technologies has minority interests in three joint ventures in Xian, China, Singapore and Macae, Brazil. For more information, visit the company’s website at

American Power Group Corp. (APGI)

American Power Group Corp.’s (OTC: APGI) alternative energy subsidiary, American Power Group, Inc., provides a cost-effective patented Turbocharged Natural Gas conversion technology for vehicular, stationary and off-road mobile diesel engines. The company’s dual fuel technology is a unique, non-invasive energy enhancement system that converts existing diesel engines into more efficient and environmentally friendly engines that have the flexibility to run on a combination of diesel and gas, with the flexibility to return to one hundred percent diesel fuel operation at any time. For more information, visit the company’s website at

Amerigo Mining & Resources (ARREF)

Amerigo Mining & Resources (OTC: ARREF) Amerigo's wholly owned subsidiary, Minera Valle Central (MVC), produces copper and molybdenum concentrates in Chile. MVC has a contractual relationship with Codelco’s El Teniente Division to treat fresh and historic tailings from the El Teniente mine, the largest underground copper mine in the world. MVC is treating the fresh tailings from El Teniente's present production and the higher grade tailings from a historic tailings deposit known as Colihues that is located near MVC's plant. For more information, visit the company’s website at

AmpliPhi Biosciences Corp. (APHB)

AmpliPhi Biosciences Corp. (OTC: APHB) is a biotech company focused on the development and commercialization of novel bacteriophage-based therapeutics that target infections that are often resistant to existing antibiotic treatments. AmpliPhi is collaborating with a number of reputable organizations, including Intrexon Corp., the U.S. Army, and UK-based University of Leicester, to rapidly advance bacteriophage-based therapies. The company is headquartered in Richmond, Va., and has operations in Colworth, UK, and Sydney, Australia. For more information, visit the company’s website at

ANI Pharmaceuticals, Inc. (ANIP)

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals with a particular focus on narcotics, anti-cancers and hormones, and extended release niche generic product opportunities. ANI manufactures oral solid dose products, as well as liquids and topicals, including narcotics and those that must be manufactured in a fully contained environment due to their potency and/or toxicity. The company also performs contract manufacturing for other pharmaceutical companies. For more information, visit the company’s website at

Antisense Therapeutics Ltd. (ATHJY)

Among Antisense Therapeutics Ltd.’s (OTCL ATHJY) pipeline of products is ATL1103, a second generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production predominantly in the liver, ATL1103 in turn reduces levels of the hormone insulin like growth factor (IGF-I) in the blood (serum). There are a number of diseases that are associated with excess GH and IGF-I. For more information, visit the company’s website at

Applied Micro Circuits Corp. (AMCC)

Applied Micro Circuits Corp. (NASDAQ: AMCC) provides computing and connectivity solutions for next-generation cloud infrastructure and data centers worldwide. AppliedMicro delivers silicon solutions that dramatically lower total cost of ownership. The company’s base business consists of a broad array of embedded computing and connectivity products. The flagship X-Gene® Server-on-a-Chip™ product leads the entire product portfolio in hyperscale data centers, and by 2016 is expected to increase overall addressable market to as much as 10x that of 2008 levels. For more information, visit the company’s website at

Applied Minerals, Inc. (AMNL)

Applied Minerals, Inc. (OTC: AMNL) produces halloysite clay from its wholly owned Dragon Mine property in Utah. Halloysite is an aluminosilicate clay that forms naturally occurring nanotubes for use in technical ceramics and catalytic applications. Applied Minerals focuses on niche applications that include, but are not limited to, carriers of active ingredients in paints, coatings and building materials, agricultural applications and high-performance fillers in plastic composites. For more information, visit the company’s Web site at

Applied Optoelectronics, Inc. (AAOI)

Applied Optoelectronics, Inc. (NASDAQ: AAOI) develops and manufactures advanced optical products that serve as building blocks for broadband fiber access networks in the CATV broadband, Internet datacenter, and fiber-to-the-home markets. The company supplies optical networking lasers, components and equipment to Tier-1 customers in all three of these markets. In addition to its corporate headquarters, wafer fab and advanced engineering and production facilities in Sugar Land, Texas, AOI has engineering and manufacturing facilities in Taipei, Taiwan, and Ningbo, China. For more information, visit the company’s website at

Apricus Biosciences, Inc. (APRI)

Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops and markets innovative treatments that have the potential to help large patient populations across numerous large-market therapeutic classes, including male and female sexual health. Apricus has one approved product, Vitaros(R), for the treatment of erectile dysfunction. Vitaros ® is approved in Europe and Canada and will be commercialized by Apricus' marketing partners. Femprox(R) is the company's product candidate for the treatment of female sexual interest/arousal disorder. For more information, visit the company’s website at

Arabella Exploration (AXPLF)

Arabella Exploration (OTC: AXPLF) is an independent oil and natural gas company focused on the acquisition, development and exploration of unconventional, long life, onshore oil and natural gas reserves in the Southern Delaware Basin in West Texas. The Company has an experienced management team with experience drilling multi-lateral wells and is primarily focused on the formations that the industry refers to as the Wolfbone play, which includes the Wolfcamp and Bone Spring shales. The Wolfbone play is characterized by high oil content and liquids rich natural gas. For more information, visit the company’s website at

Arabian American Development Company (ARSD)

Arabian American Development Company (NYSE: ARSD) owns and operates a petrochemical facility located in southeast Texas, just north of Beaumont which specializes in high purity petrochemical solvents and other solvent type manufacturing. The company is also the original developer and a 35% owner of Al Masane Al Kobra Mining Co., a Saudi Arabian joint stock company. The Company’s products are sold exclusively as intermediate components to manufacturers competing in various markets such as expandable polystyrene (styrofoam), polyethylene, adhesives, building foams, synthetic rubber and food processing. For more information, visit the company’s website at

Argex Titanium, Inc. (RGX)

Argex Titanium, Inc. (TSX: RGX) is a near-term producer of Titanium Dioxide (TiO2). With a primary goal of advancing rapidly towards production, Argex has adopted a simple and low-risk strategy for the scale-up of its proprietary process that allows it to produce high-purity pigment-grade TiO2 directly from run-of-mine material. The closed-loop process is environmentally friendly and produces minimal inert tailings. For more information, visit the company’s website at

ARI Network Services, Inc. (ARIS)

ARI Network Services, Inc. (NASDAQ: ARIS) offers eCommerce and eCatalog platforms, lead management tools and digital marketing services that help dealers, equipment manufacturers and distributors in selected vertical markets Sell More Stuff!(TM), online and in-store. The company’s products are powered by a proprietary data repository of enriched original equipment and aftermarket content that spans more than 10.5 million active part and accessory SKUs, 469,000 models and $1.7 billion in retail product value. For more information, visit the company’s website at

Arno Therapeutics, Inc. (ARNI)

Arno Therapeutics, Inc. (OTC: ARNI) is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer. Arno has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates. These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors. For more information, visit the company’s website at

Arotech Corp. (ARTX)

Arotech Corp. (NASDAQ: ARTX) provides defense and security products for the military, law enforcement and homeland security markets, including multimedia interactive simulators/trainers and advanced zinc-air and lithium batteries and chargers. Arotech operates two major business divisions: Training and Simulation and Battery and Power Systems. The company is incorporated in Delaware, with corporate offices in Ann Arbor, Mich., and research, development and production subsidiaries in Alabama, Michigan, and Israel. For more information, visit the company’s website at

Attunity, Ltd. (ATTU)

Attunity, Ltd. (NASDAQ: ATTU) is a provider of information availability software solutions that enable access, sharing and distribution of data, including Big Data, across heterogeneous enterprise platforms, organizations and the cloud. The company’s software solutions include data replication, change data capture (CDC), data connectivity, enterprise file replication (EFR) and managed-file-transfer (MFT). Attunity's software solutions enable real-time access and availability of data and files where and when needed. For more information, visit the company’s website at

Audience, Inc. (ADNC)

Audience, Inc. (NASDAQ: ADNC) provides advanced voice and audio processing for mobile devices. Its family of earSmart™ intelligent voice processors is based on the processes of human hearing, to suppress background noise and enhance mobile voice quality. Audience's technology substantially improves the mobile voice experience while also improving the performance of speech-based services, and enhancing audio quality for multimedia. Audience earSmart™ processors are featured in mobile devices from leading providers in Asia-Pacific, Europe and the U.S. For more information, visit the company’s website at

Autobytel, Inc. (ABTL)

Autobytel, Inc. (NASDAQ: ABTL) provides consumer leads and associated marketing services to automotive dealers and manufacturers throughout the United States. The company offers consumers original online automotive content to help them make informed car-buying decisions. Through its flagship website and network of automotive sites and online affiliates, Autobytel aims to provide consumers with a comprehensive automotive research and purchasing experience; and auto dealers, dealer groups and auto manufacturers with productive and cost-effective customer referral and marketing programs. For more information, visit the company’s website at

Avanir Pharmaceuticals, Inc. (AVNR)

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of its ongoing commitment, the company has extensively invested in its pipeline and is dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information, visit the company’s website at

B.O.S. Better Online Solutions Ltd. (BOSC)

B.O.S. Better Online Solutions Ltd. (NASDAQ: BOSC) provides RFID and supply chain solutions to global enterprises. The company’s RFID and mobile division offers both turnkey integration services as well as stand-alone products, including best-of-breed RFID and AIDC hardware and communications equipment, BOS middleware and industry-specific software applications. The company's supply chain division provides electronic components consolidation services to the aerospace, defense, medical and telecommunications industries as well as to enterprise customers worldwide. For more information, visit the company’s website at

Ballard Power Systems, Inc. (BLDP)

Ballard Power Systems, Inc. (NASDAQ: BLDP) provides clean energy fuel cell products to enable optimized power systems for a range of applications. The company’s products are based on proprietary esencia™ technology. Ballard has a multi-market growth focus in fuel cell products, driving greater revenue and margin potential, while lowering risk for all stakeholders. Fuel cell applications are expected to broaden in the mid-term, although the company’s focus remains sharply on commercial opportunities in backup power, distributed generation, material handling and bus applications. For more information, visit the company's website at

Barfresh Food Group, Inc. (BRFH)

Barfresh Food Group, Inc. (OTC: BRFH) is a developer, manufacturer and distributer of ready-to-blend beverages, including smoothies, shakes and frappes, primarily for restaurant chains in the quick serve restaurant and casual dining sectors. The company's proprietary, U.S. patent-pending system uses portion-controlled pre-packaged beverage ingredients that deliver freshly made smoothies that are quick, cost efficient and without waste. For more information, visit the company’s website at

Barrett Business Services, Inc. (BBSI)

Barrett Business Services, Inc. (NASDAQ: BBSI), a provider of business management solutions, combines human resource outsourcing and professional management consulting to create a unique operational platform that differentiates it from competitors. The company's integrated platform is built upon expertise in payroll processing, employee benefits, workers' compensation coverage, risk management and workplace safety programs, and human resource administration. The company works with more than 3,000 clients across all lines of business in 23 states. For more information, visit the company’s website at

Bauer Performance Sports, Ltd. (BRRPF)

Bauer Performance Sports, Ltd. (OTC: BRRPF, TSX: BAU) develops and manufactures ice hockey, roller hockey, lacrosse, baseball and softball equipment, as well as related apparel. The company’s products are marketed under the BAUER, MISSION, MAVERIK, CASCADE, INARIA and COMBAT brand names and are distributed by sales representatives and independent distributors throughout the world. Bauer Performance Sports’ goal is to strengthen its leadership position and growing market share in all product categories through continued innovation. For more information, visit the company’s website at

BIND Therapeutics, Inc. (BIND)

BIND Therapeutics, Inc. (NASDAQ: BIND) is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its Medicinal Nanoengineering® platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND’s lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase II clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. For more information, visit the company's website at

Biocept, Inc. (BIOC)

Biocept, Inc. (NASDAQ: BIOC) is a commercial stage oncology diagnostics company focused on providing information on patients' tumors to physicians using its technology platforms to help improve individual patient treatment. The company has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer. Biocept currently offers its OncoCEE-BRTM test for breast cancer and plans to introduce tests for other solid tumors. For more information, visit the company’s website at

BioCryst Pharmaceuticals, Inc. (BCRX)

BioCryst Pharmaceuticals, Inc. (BCRX) is focused on addressing unmet medical needs of patients and physicians by designing, optimizing and developing novel small molecule drugs that block key enzymes involved in infectious and rare diseases. The company’s core development programs include BCX4161 and two next generation oral inhibitors of plasma kallikrein for hereditary angioedema; peramivir, a viral neuraminidase inhibitor for the treatment of influenza; and BCX4430, a broad spectrum antiviral for hemorrhagic fevers. For more information, visit the company’s website at

Biodel, Inc. (BIOD)

Biodel, Inc. (NASDAQ: BIOD) is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. The company’s product candidates are developed by applying proprietary technologies to existing drugs in order to improve their therapeutic profiles. For more information, visit the company’s website at

BioDelivery Sciences International, Inc. (BDSI)

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a specialty pharmaceutical company leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize new applications of proven therapeutics for pain management and addiction. BioDelivery Sciences’ portfolio consists of three products: ONSOLIS® for the management of breakthrough pain in opioid tolerant, adult patients with cancer; BEMA Buprenorphine, in Phase III development for the treatment of moderate to severe chronic pain; and BUNAVAIL™, currently under FDA review for treatment of opioid dependence. For more information, visit the company’s website at

Bio Light Israeli Life Sciences Investments (BOLT)

Bio Light Israeli Life Sciences Investments (NASDAQ: BOLT) Bolt Technology Corporation is a leading worldwide developer and manufacturer of marine seismic data acquisition equipment used for offshore oil and natural gas exploration. Bolt, through its SeaBotix Inc. subsidiary, is also a developer and manufacturer of remotely operated robotic vehicles systems used for a variety of underwater tasks. For more information, visit the company’s website at

BioLineRx, Ltd. (BLRX)

BioLineRx, Ltd. (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The company’s business model is to in-license novel compounds primarily from academic institutions and biotech companies based in Israel, develop them through pre-clinical and/or clinical stages, and then partner with pharmaceutical companies for advanced clinical development and/or commercialization. BioLineRx's current portfolio consists of a range of clinical and pre-clinical projects in various stages of clinical development. For more information, visit the company’s website at

Bionomics Ltd. (BMICY)

Bionomics Ltd. (OTC: BMICY) is biopharmaceutical company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, memory loss and pain. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumors. Bionomics partners include Merck & Co and Ironwood Pharmaceuticals. For more information, visit the company’s website at

BioSpecifics Technologies Corp. (BSTC)

BioSpecifics Technologies Corp. (NASDAQ: BSTC) is a biopharmaceutical company that has developed injectable collagenase for 12 clinical indications. Injectable collagenase is approved for marketing as XIAFLEX® in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm and for Peyronie's disease in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy. BioSpecifics is currently managing the development of collagenase clostridium histolyticum for the treatment of human and canine lipomas. For more information, visit the company’s website at

Biota Pharmaceuticals, Inc. (BOTA)

Biota Pharmaceuticals, Inc. (NASDAQ: BOTA) is a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening infectious diseases. The company currently has two Phase II clinical-stage product candidates: laninamivir octanoate, for the treatment of influenza A and B; and vapendavir, a potent, oral broad spectrum capsid inhibitor of enteroviruses, including human rhinovirus. In addition to these clinical-stage development programs, Biota has preclinical programs focused on developing treatments for respiratory syncytial virus. For more information, visit the company’s website at

BJ's Restaurants, Inc. (BJRI)

BJ's Restaurants, Inc. (NASDAQ: BJRI) owns and operates casual dining restaurants in the United States under the BJ’s Restaurant & Brewery brand name, which includes a brewery within the restaurant; BJ’s Restaurant & Brewhouse brand name that receives the beer it sells from one of its breweries or an approved contract brewer of its proprietary recipe beers; and BJ’s Pizza & Grill brand name, which is a smaller format, full service restaurant. As of February 16, 2012, BJ’s owned and operated 115 casual dining restaurants. For more information visit the company’s Web site at

Black Diamond, Inc. (BDE)

Black Diamond, Inc. (NASDAQ: BDE) designs, manufactures and markets active outdoor performance products for climbing, mountaineering, backpacking, skiing, cycling and other outdoor recreation activities. The company's principal brands are: Black Diamond®, Gregory™, POC™ and PIEPS™, sold by specialty retailers in the U.S. and 50 countries around the world. Headquartered in Salt Lake City, the company's products are created and tested on some of the best alpine peaks, slopes, crags, roads and trails in the world. For more information, visit the company’s website at

Blue Earth, Inc. (BLUU)

Blue Earth, Inc. (OTC: BBLU) is engaged in the clean technology industry with a primary focus on the energy efficiency and renewable energy sectors. We strive to participate in the global movement for a sustainable planet by offering products and services that will optimize energy use, reduce harmful environmental emissions and substantially reduce energy costs to its customers. For more information, visit the company’s website at

Brainstorm Cell Therapeutics, Inc. (BCLI)

Brainstorm Cell Therapeutics, Inc. (OTC: BCLI) is a biotech company developing first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS) and Parkinson’s disease (PD). Brainstorm Cell Therapeutics holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company’s website at

Broadwind Energy, Inc. (BWEN)

Broadwind Energy, Inc. (NASDAQ: BWEN) applies provides innovative, integrated solutions for customers in the energy and infrastructure markets. With production facilities located in Manitowoc, Wis., and Abilene, Texas, Broadwind is situated in close proximity to the primary U.S. domestic energy and equipment manufacturing locations. The company’s offerings range from gears and gearing systems for wind, oil and gas and mining applications, to wind towers, to comprehensive remanufacturing of gearboxes and blades, to operations and maintenance services, and industrial weldments. For more information, visit the company’s website at

BSD Medical Corp. (BSDM)

BSD Medical Corp. (NASDAQ: BSDM) develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy. The company’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. The company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. For more information, visit the company’s website at

Burcon NutraScience Corp. (BUR)

Burcon NutraScience Corp. (NASDAQ: BUR) develops functionally and nutritionally valuable plant-based proteins. The company has developed a portfolio of composition, application, and process patents originating from a core protein extraction and purification technology. Burcon's CLARISOY™ soy protein offers clarity and high-quality protein nutrition for low pH beverage systems; Peazazz® is a uniquely soluble and clean-tasting pea protein; and Puratein®, Supertein™ and Nutratein® are canola protein isolates with unique functional and nutritional attributes. For more information, visit the company’s website at

Calavo Growers, Inc. (CVGW)

Calavo Growers, Inc. (NASDAQ: CVGW) markets and distributes avocados and other perishable foods ranging from tomatoes to tropical produce. The Calavo Foods business segment manufactures and distributes guacamole, guacamole hummus, salsa and tortilla chips under the Calavo brand name. Calavo Foods’ wholly owned subsidiary, Renaissance Food Group, LLC, creates, markets and distributes a portfolio of healthy, high-quality lifestyle products for consumers through fast-growing brands that include Garden Highway and Chef Essentials. For more information, visit the company’s website at

Callidus Software, Inc. (CALD)

Callidus Software, Inc. (NASDAQ: CALD), doing business as CallidusCloud, is a leading global market and technology player in cloud computing and sales effectiveness. CallidusCloud’s comprehensive SaaS suite is designed to assist businesses drive more effective sales. The award-winning CallidusCloud platform includes the Hiring Cloud, the Sales Enablement Cloud, the Sales Performance Cloud, the Learning Cloud, and a best-in-class SaaS Reporting & Analytics platform. For more information visit the company’s Web site at

Calpian's, Inc. (CLPI)

Calpian's, Inc.’s (OTC: CLPI) wholly owned subsidiary, Calpian Commerce, provides the merchant community with an integrated suite of payment processing services and related software enabling products. Calpian Commerce offers credit and debit card processing, ACH, mobile acceptance and gateway payment solutions to merchants in the U.S. Since April 2012, Calpian's Indian subsidiary, Money-on-Mobile, a pre-paid mobile payment solution, has been accessed by approximately 82 million unique telephone number customers at over 176,000 Indian retail locations. For more information, visit the company’s website at

CAMAC Energy, Inc. (CAK)

CAMAC Energy, Inc. (AMEX: CAK) is an independent oil and gas exploration and production company focused on energy resources in Africa. Its asset portfolio consists of 8 production and exploration licenses in 3 countries covering an area of 41,000 square kilometers (~10 million acres), including existing production and other major projects offshore Nigeria, as well as exploration licenses with significant hydrocarbon potential onshore and offshore Kenya, and offshore Gambia. CAMAC Energy is headquartered in Houston, Texas, and is listed on the New York and Johannesburg Stock Exchanges. For more information, visit the company’s website at

Camtek Ltd. (CAMT)

Camtek Ltd. (NASDAQ: CAMT) provides automated and technologically advanced solutions designed to enhance production processes and increasing yields, enabling and supporting customer's latest technologies in the semiconductors, printed circuit boards (PCB) and IC substrates industries. The company’s solutions are based on a wide and advanced platform of technologies, including intelligent imaging, image processing, adaptive ion milling (AIM) and digital material deposition (DMD). Camtek's solutions range from micro-to-nano by applying its technologies to the industries' specific requirements. For more information, visit the company’s website at

Can-Fite BioPharma Ltd. (CANF)

Can-Fite BioPharma Ltd. (NYSE: CANF), an Israeli public company, is focused on the development of small molecule orally bioavailable drugs, in particular, ligands that bind to the A3 adenosine receptor. Such drugs mediate anti-inflammatory and anti-cancer effects and the A3AR is developed as a biological predictive marker. The company’s portfolio includes lead drug candidate, CF101, which is in clinical development for the treatment of autoimmune inflammatory diseases; CF102 for the treatment of liver diseases; and CF602 for the treatment of inflammation and sexual dysfunction. For more information, visit the company’s website at

Canadian Solar, Inc. (CSIQ)

Canadian Solar, Inc. (NASDAQ: CSIQ) is a vertically integrated provider of solar modules in solar products and solar power plants with operations in North America, South America, Europe, Africa, the Middle East, Australia and Asia. Canadian Solar has delivered more than 6 GW of premium quality solar modules to customers in more than 70 countries. The company is committed to improving the environment and providing advanced solar energy products, solutions and services to enable sustainable development. For more information, visit the company’s website at

Capricor Therapeutics, Inc. (CAPR)

Capricor Therapeutics, Inc. (OTC: CAPR) is a biotechnology company focused on the development of novel therapeutics to prevent and treat heart disease. The company has two leading product candidates: CAP-1002 and Cenderitide. The company was formed through the November 2013 merger between Capricor, Inc., a privately held company whose mission is to improve the treatment of heart disease by commercializing cardiac stem cell therapies for patients, and Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular diseases. For more information, visit the company’s website at

Capstone Turbine Corp. (CPST)

Capstone Turbine Corp. (NASDAQ: CPST) is a global producer of low-emission microturbine systems. The company was the first to market commercially viable microturbine energy products, and has shipped approximately 7,000 award-winning Capstone Microturbine systems to customers worldwide. The company is a member of the U.S. Environmental Protection Agency's Combined Heat and Power Partnership. The company is headquartered in the Los Angeles area with sales and/or service centers in the New York Metro Area, United Kingdom, Mexico City, Shanghai and Singapore. For more information, visit the company’s website at

CAS Medical Systems, Inc. (CASM)

CAS Medical Systems, Inc. (NASDAQ: CASM) develops and manufactures medical devices designed to provide unique, non-invasive patient monitoring solutions that are vital to patient care. The company’s FORE-SIGHT Absolute Cerebral Oximeter provides an accurate, continuous measurement of cerebral tissue oxygen saturation, a powerful tool for alerting clinicians to otherwise unrecognized and dangerously low levels of oxygenation in the brain and other tissues so they can intervene, where necessary, in the care of their patients. For more information, visit the company’s website at

Cash America International, Inc. (CSH)

Cash America International, Inc. (NYSE: CSH) provides specialty financial services to individuals in the United States and Mexico. The company provides secured pawn loans under the brand names Cash America Pawn, SuperPawn and Prenda Fácil; and short-term cash advances under the brand names Cash America Payday Advance and Cashland. Short-term cash advances are offered over the Internet to customers in the U.S., the UK, Australia and Canada. Check-cashing services are provided through the company’s Mr. Payroll check-cashing centers. For more information, visit the company’s website at

Catalyst Pharmaceutical Partners, Inc. (CPRX)

Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX) is focused on the development and commercialization of novel prescription drugs targeting rare neuromuscular and neurological diseases. The company’s lead candidate, Firdapse™ for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) recently received Breakthrough Therapy Designation from the U.S. FDA. Catalyst is also developing CPP-115, which has been granted U.S. orphan drug designation for the treatment of infantile spasms by the FDA and has been granted E.U. orphan medicinal product designation for the treatment of West Syndrome by the European Commission. For more information, visit the company’s website at

Catasys Health (CATS)

Catasys Health (OTC: CATS) provides specialized health management services to health plans and employers through a network of licensed and company managed health care providers. The Catasys substance dependence program improves member health, thereby lowering overall costs. The proprietary program addresses substance dependence as a chronic disease, focusing on the whole health of the member. The program delivers integrated medical and psychosocial interventions in combination with long-term care coaching. For more information, visit the company’s website at

Cavium (CAVM)

Cavium (NASDAQ: CAVM) is a leading provider of highly integrated semiconductor products that enable intelligent processing in networking, communications and the digital home. Cavium offers a broad portfolio of integrated, software compatible processors ranging in performance from 100 Mbps to over 100 Gbps that enable secure, intelligent functionality in enterprise, data-center, broadband/consumer and access & service provider equipment. For more information, visit the company’s website at

Cell Therapeutics, Inc. (CTIC)

Cell Therapeutics, Inc. (NASDAQ: CTIC) a biopharmaceutical company focused on the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. The company’s goal is to acquire, develop and bring to market less toxic, more effective cancer treatments. Cell Therapeutics therapeutic focus is on novel targeted therapies covering a range of blood-related cancers. For more information, visit the company’s website at

Celldex Therapeutics, Inc. (CLDX)

Celldex Therapeutics, Inc. (NASDAQ: CLDX) is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. The company’s pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. For more information, visit the company’s website at

Chelsea Therapeutics International Ltd. (CHTP)

Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) is a biopharmaceutical development company engaged in the acquisition and commercialization of innovative products for the treatment of a variety of human diseases, including central nervous system disorders. Chelsea acquired global development and commercialization rights to droxidopa (L-DOPS), or NORTHERA, from Dainippon Sumitomo Pharma Co., Ltd. in 2006, excluding Japan, Korea, China and Taiwan. For more information, visit the company’s website at

China Cord Blood Corp. (CO)

China Cord Blood Corp. (NYSE: CO) is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. The company provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. Under current People’s Republic of China government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. For more information, visit the company’s website at

Cempra, Inc. (CEMP)

Cempra, Inc. (NASDAQ: CEMP) is a late clinical-stage pharmaceutical company focused on developing antibiotics to treat critical bacterial infections in patients in both acute and primary care settings. The company’s two lead product candidates (CEM-101, CEM-102) are currently in advanced clinical development to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to use its series of proprietary lead compounds for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. For more information, visit the company’s website at

Cherokee Inc. (CHKE)

Cherokee Inc. (NASDAQ: CHKE) is a global marketer and manager of a portfolio of Fashion and Lifestyle brands including Cherokee®, Carole Little®, Liz Lange® and Sideout®, in multiple consumer product categories and sectors around the world. The company has license agreements with premier retailers and manufacturers covering over 40 countries around the world including the United States, the UK, Ireland and certain Central European countries, Peoples Republic of China, South Africa, Chile, Peru and Colombia, India and certain Middle Eastern countries, Israel, Mexico, Spain, Japan, Russia and more. For more information, visit the company’s website at

ChromaDex Corp. (CDXC)

ChromaDex Corp. (OTC: CDXC) is a natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. For more information, visit the company’s website at

Cimatron Group (CIMT)

Cimatron Group (NASDAQ: CIMT) provides integrated, CAD/CAM software solutions for mold, tool and die makers, as well as manufacturers of discrete parts. The company’s product line includes the CimatronE and GibbsCAM brands with solutions for mold design, die design, electrodes design, 2.5 to 5 axes milling, wire EDM, turn, mill-turn, rotary milling, multi-task machining, and tombstone machining. Cimatron's subsidiaries and distribution network serve and support customers in the automotive, aerospace, medical, consumer plastics, electronics, and other industries in over 40 countries worldwide. For more information, visit the company’s website at

Cinedigm Corp. (CIDM)

Cinedigm Corp. (NASDAQ: CIDM) is a leader in providing the services, experience, technology and content critical to transforming movie theaters into digital and networked entertainment centers. Cinedigm partners with Hollywood movie studios, independent movie distributors, and exhibitors to bring movies in digital cinema format to audiences across the country. Cinedigm's digital cinema deployment organization, state of the art distributor and exhibition software, and marketing and distribution platform for alternative content and independent films are a cornerstone of the digital cinema transformation. For more information, visit the company’s website at

Circadian Technologies Ltd. (CKDXF)

Circadian Technologies Ltd. (OTC: CKDXF) is developing a variety of drugs to block the interaction between VEGF Receptor-3 (VEGFR-3) and its ligands VEGF-C and VEGF-D. Drugs blocking this pathway would represent a novel and potentially revolutionary treatment approach for the treatment of cancer and eye disease, particularly corneal disease. Circadian holds an extensive intellectual property position protecting its rights as the exclusive developer of drugs within this category. For more information, visit the company’s website at

Clean Diesel Technologies Inc. (CDTI)

Clean Diesel Technologies Inc. (NASDAQ: CDTI) is a vertically integrated global manufacturer and distributor of emissions control systems and products for the heavy duty diesel and light duty vehicle markets. CDTi utilizes its proprietary patented Mixed Phase Catalyst (MPC®) technology, as well as its ARIS® selective catalytic reduction, Platinum Plus® fuel-borne catalyst, and other technologies to reduce emissions, increase energy efficiency and lower the carbon intensity of on- and off-road engine applications. CDTi is headquartered in California and currently has operations in the U.S., Canada, France, Japan and Sweden. For more information, visit the company’s website at

Clean Energy Fuels Corp. (CLNE)

Clean Energy Fuels Corp. (NASDAQ: CLNE) is the largest provider of natural gas fuel for transportation in North America. We build and operate compressed natural gas (CNG) and liquefied natural gas (LNG) fueling stations; manufacture CNG and LNG equipment and technologies for ourselves and other companies; develop renewable natural gas (RNG) production facilities; and deliver more CNG, LNG and Redeem RNG fuel than any other company in the U.S. For more information, visit the company’s website at

ClearSign Combustion Corp. (CLIR)

ClearSign Combustion Corp. (NASDAQ: CLIR) designs and develops technologies that aim to improve key performance characteristics of combustion systems including energy efficiency, emissions control, fuel flexibility and overall cost effectiveness. The company’s Electrodynamic Combustion Control™ (ECC™) platform technology improves control of flame shape and heat transfer and optimizes the complex chemical reactions that occur during combustion in order to minimize harmful emissions. For more information, visit the company’s website at

Coastal Contacts, Inc. (COA)

Coastal Contacts, Inc. (NASDAQ: COA) is a manufacturer and online retailer of eyewear products offered through a family of websites. Established in 2000, the brand family offers an in-stock selection of prescription eyewear, contact lenses and sunglasses.'s vision is to make the process simple, either online or at one of its retail showrooms. The company’s glasses and contacts are the same designer brands and styles that you will find in tradition retail outlets but are sold at a reduced price. For more information, visit the company’s website at

CombiMatrix Corp. (CBMX)

CombiMatrix Corp. (NASDAQ: CBMX) operates through its wholly owned subsidiary CombiMatrix Diagnostics (CMDX) as a molecular diagnostics laboratory offering DNA-based testing services for the prenatal, pediatric and oncology markets. CMDX’s prenatal and pediatric testing services detect abnormalities of genes at the DNA level beyond what can be identified through traditional technologies. CMDX was the first commercial clinical laboratory in the United States to make comprehensive DNA-based genomic analysis of solid tumors available to oncology patients and medical professionals. For more information, visit the company’s Web site at

Conatus Pharmaceuticals, Inc. (CNAT)

Biotechnology company Conatus Pharmaceuticals, Inc. (NASDAQ: CNAT) concentrates on the development and commercialization of medicines to treat liver disease. Conatus is developing emricasan as an orally active caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death, or apoptosis. Conatus believes that by reducing the activity of these enzymes, emricasan has the potential to interrupt the progression of liver disease. For more information, visit the company’s website at

Concert Pharmaceuticals, Inc. (CNCE)

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel small molecule drugs. This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety, tolerability and efficacy. The company is developing a broad pipeline targeting CNS disorders, renal disease, inflammation and cancer. For more information, visit the company’s website at

Concur Technologies, Inc. (CNQR)

Concur Technologies, Inc. (NASDAQ: CNQR), a provider of integrated travel and expense management solutions, has developed web-based and mobile solutions designed to assist companies, federal agencies and their employees in their ability to control costs and save time. The company’s open platform enables the entire travel and expense ecosystem of customers, suppliers, and developers to access and extend the company's T&E cloud. Concur's systems are created to adapt to individual employee preferences and scale to meet the needs of both large and small enterprises. For more information, visit the company’s website at

Consolidated Water Co. Ltd. (CWCO)

Consolidated Water Co. Ltd. (NASDAQ: CWCO) develops and operates seawater desalination plants and water distribution systems in areas of the world where natural supplies of potable water are scarce or nonexistent. The company operates water production and/or distribution facilities in the Cayman Islands, Belize, the British Virgin Islands, The Commonwealth of The Bahamas, and Bali, Indonesia. Headquartered in George Town, Grand Cayman Islands, the company’s customer base is comprised of government-owned utilities, private bulk water customers and retail customers. For more information, visit the company’s website at

Constant Contact, Inc. (CTCT)

Constant Contact, Inc. (NASDAQ: CTCT) specializes in turnkey e-mail marketing programs that help small organizations create and grow customer relationships. The company primarily targets small businesses, nonprofits, and associations worldwide with their online marketing tools and programs. The company’s clients look to benefit through the generation of new customers, repeat business, and referrals through e-mail marketing, social media marketing, event marketing, local deals, digital storefronts, and online surveys. For more information, visit the company’s website at

CopyTele, Inc. (COPY)

CopyTele, Inc. (OTC: COPY) develops and acquires patented technologies for the purposes of patent monetization and patent assertion. The company currently has nine patent portfolios in the areas of Key Based Web Conferencing Encryption, Encrypted Cellular Communications, E-Paper® Electrophoretic Display, Nano Field Emission Display ("nFED"), Micro Electro Mechanical Systems Display ("MEMS"), Loyalty Conversion Systems, J-Channel Window Frame Construction, VPN Multicast Communications, and Internet Telephonic Gateway. For more information, visit the company’s website at

CorMedix, Inc. (CRMD)

CorMedix, Inc. (AMEX: CRMD) is a commercial-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. CorMedix's first commercial product is Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients. For more information, visit the company’s website at

Cortex Business Solutions, Inc. (CTXZF)

Cortex Business Solutions, Inc. (OTC: CTXZF, CBX.V) is an enterprise eProcurement solutions company that improves efficiencies, reduces costs and streamlines procurement and supply chain processes for its customers. Accessing the Cortex Network enhances the exchange of business critical documents, such as purchase orders, receipts and invoices, resulting in improved cash flow management and business controls, while reducing day's outstanding and administrative costs. Cortex is a low cost, low risk solution that can be implemented quickly by leveraging clients' existing business environment. For more information, visit the company’s website at

CPI Aerostructures, Inc. (CVU)

CPI Aerostructures, Inc. (NYSE: CVU) is a U.S. manufacturer of structural aircraft parts for fixed wing aircraft and helicopters in the commercial and defense markets. The company is a Tier 1 supplier to aircraft OEMs or a Tier 2 subcontractor to Tier 1 manufacturers. As a prime contractor to the U.S. Department of Defense, CPI’s primary focus is with the Air Force. Along with its assembly operations, the company provides engineering, program management and supply chain management. For more information, visit the company’s website at

Craft Brew Alliance, Inc. (BREW)

Craft Brew Alliance, Inc. (NASDAQ: BREW) is a publicly traded craft brewing company that was formed in 2008 through the merger of Pacific Northwest craft brewers Widmer Brothers Brewing and Redhook Ale Brewery. With intentions to preserve and grow one-of-a-kind craft beers and brands, CBA welcomed Kona Brewing Company, (headquartered in Kailua-Kona, Hawaii), in 2010, and then launched Omission beer (headquartered in Portland, Ore.) in 2012 and Square Mile Cider Company in 2013. For more information, visit the company’s website at:

CRAiLAR Technologies, Inc. (CRLRF)

CRAiLAR Technologies, Inc. (OTC: CRLRF) offers cost-effective and environmentally sustainable natural fiber in the form of flax, hemp and other bast fibers for use in textile, industrial, energy, medical and composite material applications. The company supplies its CRAiLAR Flax to IKEA, HanesBrands, Georgia-Pacific, Tuscarora Yarns, Target Corp., Cone Mills Cotswold Industries and Kowa Company for commercial use, and to Levi Strauss & Co., Ashland, PVH Corp. and Lenzing for evaluation and development. For more information, visit the company’s website at

Crown Crafts, Inc. (CRWS)

Crown Crafts, Inc. (NASDAQ: CRWS) designs, markets and distributes infant, toddler and juvenile consumer products. The company's products include licensed and branded collections and private label programs for some customers. Consumer product lines consist of crib and toddler bedding, blankets, nursery accessories, room décor, burp cloths, bathing accessories, disposable placemats, floor mats, toilet seat covers and changing mats. Operating subsidiaries consist of Crown Crafts Infant Products, Inc., located in California, and Hamco, Inc. in Louisiana. For more information, visit the company’s website at

Curis, Inc. (CRIS)

Focused on oncology drug development, Curis, Inc. (NASDAQ: CRIS) seeks to develop novel drug candidates for the treatment of human cancers. The company also seeks to further the development of its pipeline of proprietary targeted cancer drug candidates, including CUDC-907, a dual HDAC, PI3K inhibitor, and CUDC-427, a small molecule antagonist of IAP proteins. Curis-discovered HSP90 inhibitor Debio 0932 is being studied in patients with advanced lung and kidney cancers by partner Debiopharm. For more information, visit the company’s website at

Cutera, Inc. (CUTR)

Cutera, Inc. (NASDAQ: CUTR) provides laser and other light-based aesthetic systems for practitioners on a global scale. Cutera’s products are designed to enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. Cutera’s key solutions include hair removal, non-ablative and skin laxity, fractional and ablative resurfacing, and treatment for vascular conditions such as leg veins. For more information, visit the company’s website at

CyberOptics Corp. (CYBE)

CyberOptics Corp. (NASDAQ: CYBE) provides optical sensors and inspection systems for printed circuit board assembly, sensors for semiconductor wafer fabrication, and frame grabbers. CyberOptics’ technology is used by electronics manufacturers to solve industry challenges and increase productivity and product quality. The company’s customer base includes manufacturing plants around the world. For more information, visit the company’s website at

CymaBay Therapeutics, Inc. (CYMA)

CymaBay Therapeutics, Inc. (OTC: CYMA) is a clinical-stage biopharmaceutical company developing breakthrough therapies addressing unmet medical needs. Arhalofenate, the company's lead product candidate, possesses two therapeutic actions in a single drug. In gout patients, arhalofenate is intended to prevent painful attacks in joints while at the same time promoting excretion of uric acid by the kidney, thereby removing the root cause of this debilitating disease. For more information, visit the company’s website at


CYREN (NASDAQ: CYRN) Following years of being positioned as a small component of email and web security, CYREN has started down a new path. It is in the process of building out a full cloud-based product line that can be sold white label to vendors such as telecommunication and storage providers to protect their customers. Cloud-based security is on the rise according to Gartner who predicts that the industry will grow to $4.1B in 2017. This is an annual compound growth rate of 18.2% from its highs in 2013. For more information, visit the company’s website at

Cytokinetics, Inc. (CYTK)

Cytokinetics, Inc. (NASDAQ: CYTK) is focused on its goal to become a fully integrated biopharmaceutical company intent on discovering, developing and commercializing novel small molecule drugs that looks to address areas of significant unmet clinical needs. With research in areas of the cytoskeleton, muscle biology and cell cycle control, the company’s lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the potential treatment of heart failure. For more information, visit the company’s website at

Cytori Therapeutics, Inc. (CYTX)

Cytori Therapeutics, Inc. (NASDAQ: CYTX) develops cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. The company’s research suggests that ADRCs improve blood flow, moderates the inflammatory response, and keeps tissue at risk of dying alive. As a result, the company is of the opinion that these cells have application across multiple “ischemic” conditions. These therapies are made available to the physician and patient at the point-of-care by the company’s proprietary technologies and products, including the Celution System product family. For more information, visit the company’s website at

DARA BioSciences, Inc. (DARA)

DARA BioSciences, Inc. (NASDAQ: DARA) is an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments. DARA holds exclusive U.S. marketing rights to Soltamox® oral solution for the treatment and prevention of breast cancer. Soltamox offers a choice to patients who prefer or need a liquid form of tamoxifen. For more information, visit the company’s website at

Del Mar Pharmaceuticals, Inc. (DMPI)

Founded in 2010, Del Mar Pharmaceuticals, Inc. (OTC: DMPI) develops and commercializes proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute (NCI), and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. For more information, visit the company’s website at

Delta Apparel, Inc. (DLA)

Delta Apparel, Inc. (NYSE: DLA), in conjunction with its operating subsidiaries, M. J. Soffe, LLC, Junkfood Clothing Company, To The Game, LLC and Art Gun, LLC, is an international design, marketing, manufacturing, and sourcing company featuring a portfolio of lifestyle basic and branded active-wear apparel and headwear. The company specializes in selling casual and athletic products across distribution tiers such as specialty stores, boutiques, department stores, mid-tier and mass chains, college bookstores and the U.S. military. For more information, visit the company’s website at

Depomed, Inc. (DEPO)

Depomed, Inc. (NASDAQ: DEPO) is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. The company was founded in 1995 and has established itself by developing and incorporating promising technology into differentiated therapeutic products, taking those products through clinical approval, and building a strong market presence. The company currently markets three FDA-approved products, Gralise® (gabapentin), Cambia® (diclofenac potassium for oral solution), Zipsor® (diclofenac potassium) and Lazanda® (fentanyl). The company is headquartered in Newark, Calif. For more information, visit the company’s website at

Derma Sciences, Inc. (DSCI)

Derma Sciences, Inc. (NASDAQ: DSCI) is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products; advanced wound care dressings to address chronic wounds including diabetic ulcers; and traditional dressings. The company is in Phase III clinical trials in diabetic foot ulcer healing with DSC127, based on Phase II data. During the third quarter of 2014, Derma Sciences expects to begin marketing AmnioMatrix®, a portfolio of two human placental-derived tissue products for wound healing. For more information, visit the company’s website at

Destination Maternity Corp. (DEST)

Destination Maternity Corp. (NASDAQ: DEST) is a global designer and retailer of maternity apparel. In the United States and Canada, as of September 30, 2012, the company operates 1,907 retail locations, including 596 stores, predominantly under the trade names Motherhood® Maternity, A Pea in the Pod®, and Destination Maternity®, and 1,311 leased department locations. The company sells on the web through its and brand-specific websites and is headquartered in Philadelphia, Penn. For more information, visit the company’s website at

Destiny Media Technologies Inc. (DSNY)

Destiny Media Technologies Inc., (OTC: DSNY) develops and markets digital media software solutions principally in the United States, Europe, and Australia. Its solutions and technologies allow the distribution of digital media files through the Internet either in a streaming or digital download format. The company offers Play MPE, a digital delivery service for moving broadcast audio, video, images, promotional information, and other digital content through the Internet; Clipstream Legacy, a playerless streaming video solution; and Clipstream G2, a cross platform that eliminates costs associated with re-encoding videos into multiple formats. For more information, visit the company’s website at

Dexcom, Inc. (DXCM)

Dexcom, Inc. (NASDAQ: DXCM), headquartered in San Diego, Calif., is developing and marketing continuous glucose monitoring systems for ambulatory use by patients and by healthcare providers in the hospital. Founded in 1999, Dexcom's roots stem from the 1967 research of Dr. Updike and Hicks on implantable glucose sensors that the body would not reject and that would perform for a long period of time. That founding year, the research, Dr. Updike, joined Dexcom to innovate further. For more information, visit the company’s website at

Diamcor Mining Inc. (DMIFF)

Diamcor Mining Inc. (OTC: DMIFF, V.DMI) is a junior diamond mining company with a well-established operational and production history in South Africa, extensive experience supplying rough diamonds to the world market, and has established a long-term strategic alliance with world famous Tiffany & Co. Rather than exposing itself to the high risks and costs associated with exploration, the company's focus is on the identification, acquisition, and operation of unique diamond projects with near-term production potential such as the Krone-Endora at Venetia Project. For more information, visit the company’s website at

Document Security Systems, Inc. (DSS)

Document Security Systems, Inc. (NYSE: DSS) develops and provides patented anti-counterfeiting, anti-fraud, authentication and brand protection technologies used by governments, corporations and financial institutions worldwide. DSS’ proprietary technology solutions deter unauthorized scanning and copying, and facilitate authentication of printed documents and packaging. The company also helps to reduce fraud in drug prescription redemptions and health insurance documents. DSS product solutions are protected under U.S. and foreign patent law and under trade secrets. For more information, visit the company’s website at

Dot Hill Systems, Corp. (HILL)

Dot Hill Systems, Corp. (NASDAQ: HILL) utilizes proprietary assured family of storage solutions to solve many of today's challenging storage problems. The company helps IT environments to improve performance, increase availability, simplify operations, and reduce costs. Dot Hill’s solutions combine software applications with a flexible hardware platform and automated management to deliver best-in-class solutions. Headquartered in Longmont, Colo., the company has offices and/or representatives in China, Germany, India, Japan, Singapore, the United Kingdom, and the United States. For more information, visit the company’s website at

Durata Therapeutics, Inc. (DRTX)

Durata Therapeutics, Inc. (NASDAQ: DRTX) is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The company has completed two global Phase III clinical trials with its lead product, dalbavancin, for the treatment of patients with complicated skin and soft tissue infections, or cSSTI (or, in the U.S., acute bacterial skin and skin structure infections -- ABSSSI). Company executives formed Durata Therapeutics in 2009 and established its first corporate headquarters in Morristown, New Jersey. For more information, visit the company’s website at

Echo Therapeutics, Inc. (ECTE)

Echo Therapeutics, Inc. (NASDAQ: ECTE) is developing the Symphony CGM System as a non-invasive, wireless, continuous glucose monitoring system for use initially in the critical care setting. Symphony’s opportunity for use in the hospital and critical care settings also extends into application among patients with diabetes in the outpatient setting. The company is also developing its needle-free skin preparation component of Symphony, the Prelude® SkinPrep System, as a platform technology to deliver topical pharmaceuticals. For more information, visit the company’s website at

Edgewater Technology (EDGW)

Edgewater Technology (NASDAQ: EDGW) is a strategic consulting firm delivering a blend of classic and product-based consulting services. Edgewater addresses the market both vertically by industry and horizontally by product and technology specialty, providing its client base with a wide range of business and technology solutions. As one of the largest IT consulting firms based in New England, the company works with clients to reduce costs, improve processes and increase revenue through the judicious use of technology. For more information, visit the company’s website at

Electro Scientific Industries, Inc. (ESIO)

Electro Scientific Industries, Inc. (NASDAQ: ESIO) leading supplier of innovative, laser-based manufacturing solutions for the microtechnology industry. The company’s systems enable precise structuring and testing of micron to submicron features in smart electronic devices, semiconductors, LEDs and other high-value components. The company partners with its customers to make breakthrough technologies possible in the microelectronics, semiconductor and other emerging industries. For more information, visit the company’s website at

Elli Mae, Inc. (ELLI)

Elli Mae, Inc. (NYSE: ELLI) is a provider of on-demand automation solutions for the mortgage industry. The company offers turn-key solutions, delivered using a Software-as-a-Service model that serves as the core operating system for mortgage originators and spans customer relationship management, loan origination and business management. The company also hosts the Ellie Mae Network™ that allows Encompass® users to electronically conduct business transactions with the lenders and settlement service providers they work with to process and fund loans. For more information, visit the company’s website at

Endocyte, Inc. (ECYT)

Endocyte, Inc. (NASDAQ: ECYT) is a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases. The company uses its proprietary technology to create SMDCs and companion imaging agents for personalized therapies. The company's SMDCs actively target receptors that are expressed or over-expressed on diseased cells, relative to healthy cells. For more information, visit the company’s website at

Endologix, Inc. (ELGX)

Endologix, Inc. (NASDAQ: ELGX) develops and manufactures minimally invasive treatments for aortic disorders. The company works with endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA), which is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops it continues to enlarge, and if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. For more information, visit the company’s website at

Ener-Core, Inc. (ENCR)

Ener-Core, Inc. (OTC: ENCR) designs, develops, and manufactures gradual oxidizer products and technologies that aim to expand power generation into previously uneconomical markets, while at the same time reducing the emissions of gases produced from industrial processes that contribute to air pollution and climate change. The company’s products and technologies produce continuous energy from various sources, primarily methane gas from around the world, and its patented oxidation technology enables the conversion of unusable ultra-low quality gases into heat and power with lowest emissions. For more information, visit the company’s website at

Energy Focus, Inc. (EFOI)

Energy Focus, Inc. (OTC: EFOI) provides energy efficient LED lighting products, turnkey energy efficient lighting solutions and is a developer of energy efficient lighting technology. The company’s solutions provide energy savings, aesthetics, safety and maintenance cost benefits over conventional lighting. Its long-standing relationship with the U.S. Government includes numerous research and development projects for the DOE and DARPA, creating energy efficient LED lighting systems for the U.S. Navy fleet. For more information, visit the company’s website at

Energy Fuels, Inc. (UUUU)

Energy Fuels, Inc. (OTC: UUUU, EFR.TO) is currently America's largest conventional uranium producer, supplying approximately 25% of the uranium produced in the United States in 2013. Energy Fuels operates the White Mesa Mill, which is the only conventional uranium mill currently operating in the U.S. Energy Fuels has projects located throughout the Western U.S., including producing mines and mineral properties in various stages of permitting and development. For more information, visit the company’s website at

Enphase Energy, Inc. (ENPH)

Enphase Energy, Inc. (NASDAQ: ENPH) delivers microinverter technology for the solar industry that increases energy production, simplifies design and installation, improves system uptime and reliability, reduces fire safety risk and provides a platform for intelligent energy management. The company’s semiconductor-based microinverter system converts energy at the individual solar module level and brings a systems-based, high technology approach to solar energy generation. For more information, visit the company’s website at

Enservco Corp. (ENSV)

Through its various operating subsidiaries, Enservco Corp. (OTC: ENSV) has emerged as one of the energy service industry's providers of hot oiling, acidizing, frac heating and fluid management services. The company owns and operates a fleet of more than 230 specialized trucks, trailers, frac tanks and related well-site equipment. Enservco serves customers in seven major domestic oil and gas fields, and operates in Colorado, Kansas, Montana, New Mexico, North Dakota, Oklahoma, Pennsylvania, Ohio, Texas, Wyoming and West Virginia. For more information, visit the company’s website at

EnteroMedics, Inc. (ETRM)

Medical device company, EnteroMedics, Inc. (NASDAQ: ETRM), is focused on the development and commercialization of its neuroscience based technology to treat obesity and metabolic diseases. The company’s proprietary technology is its VBLOC® vagal blocking therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, and designed to intermittently block the vagus nerves using high-frequency, low-energy, electrical impulses. VBLOC enables obese individuals to move towards weight loss while addressing the lifelong challenge of obesity and its comorbidities without sacrificing wellbeing or comfort. For more information, visit the company’s website at

Entropic Communications, Inc. (ENTR)

Entropic Communications, Inc. (NASDAQ: ENTR) is a leader in semiconductor solutions for the connected home. The company transforms how traditional HDTV broadcast and IP-based streaming video content is delivered, processed, and distributed into and throughout the home. The company's next-generation Set-top Box (STB) System-on-a-Chip (SoC) and Connectivity solutions enable Pay-TV operators to offer consumers more whole-home entertainment experiences by transforming the way digital entertainment is delivered, connected and consumed -- in the home and on the go. For more information, visit the company’s website at

Escalade, Inc. (ESCA)

Escalade, Inc. (NASDAQ: ESCA) manufactures and sells sporting goods, and information security and print finishing products primarily in North America and Europe. It operates in two segments, Sporting Goods, and Information Security and Print Finishing. The Sporting Goods segment manufactures, imports, and distributes family recreation, fitness, training, and hunting products. The Information Security and Print Finishing segment provides shredders, disintegrators, degaussers, paper folders, letter openers, and paper cutters/trimmers under martin yale and intimus brands. For more information, visit the company’s website at

Evoke Pharma, Inc. (EVOK)

Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. EVK-001 is a novel formulation of metoclopramide, designed to provide systemic delivery of metoclopramide through intranasal administration. For more information, visit the company’s website at

Exact Sciences Corp. (EXAS)

Exact Sciences Corp. (NASDAQ: EXAS) is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer. The company’s mission is to partner with healthcare providers, payers, patients and advocacy groups to eradicate colorectal cancer. For more information, visit the company’s website at

EZchip Semiconductor Ltd. (EZCH)

EZchip Semiconductor Ltd. (NASDAQ: EZCH) is a fabless semiconductor company that provides Ethernet network processors for networking equipment. The company provides solutions that scale from a few to hundreds of Gigabits-per-second. EZchip's network processors provide flexibility and performance with integration and power efficiency for a wide range of applications in carrier, cloud and data center network equipment. EZchip Technologies was formed as a spin-off in 1999 and is fully owned by EZchip Semiconductor. For more information, visit the company’s website at


For more frequent updates, follow us on Twitter!

Home     About Us     Blog     Investors     IR Services     Market Research     Partners     Contact     Disclaimer

© 2014 Mission Investor Relations. All rights reserved.
3645 Marketplace Blvd.   Suite 130-280   Atlanta, GA 30344   404-941-8975